XML 15 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 5,794,272 $ 15,748,480
Short-term investment securities 6,847,270 4,511,780
Interest receivable 58,285 94,375
Accounts receivable 330,001 277,831
Prepaid expenses and other current assets 392,236 375,830
Total current assets 13,422,064 21,008,296
Non-current assets:    
Investment in Alphazyme 284,709 284,709
Other assets 6,045 6,117
Total assets 13,712,818 21,299,122
Current liabilities:    
Accounts payable 1,276,313 1,547,953
Accrued expenses 955,081 709,560
Deferred research and development obligations 40,743 151,147
Deferred license revenue, current portion 176,471 147,059
Total current liabilities 2,448,608 2,555,719
Deferred license revenue, net of current portion 176,471 352,941
Total liabilities 2,625,079 2,908,660
Commitments and contingencies (Note 5)
Stockholders’ equity:    
Preferred stock, $.0001 par value: Authorized shares - 5,000,000; none issued and outstanding 0 0
Common stock, $.001 par value:Authorized shares - 100,000,000; issued shares - 40,332,659 and 39,747,659, outstanding shares - 28,079,157 and 27,494,157 as of June 30, 2021, and December 31, 2020, respectively 40,817 40,483
Additional paid-in capital 103,458,697 101,026,496
Treasury stock, shares held at cost - 12,253,502 (18,929,915) (18,929,915)
Accumulated deficit (73,481,860) (63,746,602)
Total stockholders’ equity 11,087,739 18,390,462
Total liabilities and stockholders’ equity $ 13,712,818 $ 21,299,122